Table 4.
Univariate and Multivariable Logistical Regression Analysis of Risk Factors for Pazopanib-Induced Hypertension
| Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|
|
| ||||
| OR | P-value | OR | P-value | |
| Age ≥ 60 years | 0.81 | 0.767 | ||
| Male (vs. female) | 1.31 | 0.694 | ||
| Baseline SBP ≥ 130 mmHg | 5.32 | 0.058 | 4.62 | 0.197 |
| Antihypertensive therapy at baseline | ||||
| ACEIs or ARBs | 4.88 | 0.044 | 4.31 | 0.075 |
| Calcium channel blockers | 3.5 | 0.160 | ||
| Diuretics | 2.17 | 0.400 | ||
| Beta-blockers | 0.5 | 0.348 | ||
| ≥ 2 Antihypertensives | 4 | 0.078 | ||
| Baseline CV Risk Factors | ||||
| Diabetes | 1.23 | 0.767 | ||
| GFR < 60 ml/min/1.73m2 | 0.81 | 0.767 | ||
| BMI > 30 kg/m2 | 0.76 | 0.694 | ||
| Smokera | 2.12 | 0.281 | ||
| Oncologic Profile | ||||
| Prior Nephrectomy | 0.75 | 0.687 | ||
| Pazopanib starting dose 800 mg | 0.64 | 0.724 | ||
OR odds ratio, SBP systolic blood pressure, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CV cardiovascular, GFR glomerular filtration rate, BMI body mass index, ECOG Eastern Cooperative Oncology Group performance status
a
Current of past smoker